• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table 35Biologic DMARD plus oral DMARD versus biologic DMARD plus oral DMARD studies: Functional capacity and health-related quality-of-life outcomes

StudyStudy Design
N
Duration
Study PopulationComparison (dose)Functional CapacityHealth-Related Quality of LifeQuality Rating
Anti-TNF+MTX vs. Anti-TNF+LEF
*Finckh et al., 200894
SCQM cohort
Prospective Cohort
1,218
17 months (mean)
Population-based: Treatment with INF, ETN or ADA; mean disease duration 8.4 to 8.9 yearsAnti-TNF (INF or ETN or ADA) (NR)+MTX (NR) vs. Anti-TNF (INF or ETN or ADA) (NR)+LEFMean improvement in HAQ at 1 year: 0.12 vs. 0.14; P=0.09NRFair
*

New study added since last review.

ADA = adalimumab; ETN = etanercept; HAQ = Health Assessment Questionnaire; INF = infliximab; LEF = leflunomide; NR = not reported; SCQM = Swiss Clinical Quality Management; TNF = tumor necrosis factor

New study added since last review.

From: Results

Cover of Drug Therapy for Rheumatoid Arthritis in Adults: An Update
Drug Therapy for Rheumatoid Arthritis in Adults: An Update [Internet].
Comparative Effectiveness Reviews, No. 55.
Donahue KE, Jonas DE, Hansen RA, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.